$4.15
6.36%
Downside
Day's Volatility :8.35%
Upside
2.12%
30.28%
Downside
52 Weeks Volatility :52.17%
Upside
31.4%
Period | Genfit Sa | Index (Russel 2000) |
---|---|---|
3 Months | -23.57% | 0.0% |
6 Months | 16.41% | 0.0% |
1 Year | 7.79% | 0.0% |
3 Years | 1.22% | -22.3% |
Market Capitalization | 211.0M |
Book Value | $1.37 |
Earnings Per Share (EPS) | -0.64 |
Profit Margin | -83.79% |
Operating Margin TTM | -56.31% |
Return On Assets TTM | -9.91% |
Return On Equity TTM | -35.57% |
Revenue TTM | 34.5M |
Revenue Per Share TTM | 0.69 |
Quarterly Revenue Growth YOY | 37.3% |
Gross Profit TTM | 26.2M |
EBITDA | -29.3M |
Diluted Eps TTM | -0.64 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 78.5K | ↓ 41.53% |
Net Income | -90.5M | ↑ 35.69% |
Net Profit Margin | -115.2K% | ↓ 65583.42% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 34.3M | ↑ 44594.2% |
Net Income | -72.4M | ↓ 18.08% |
Net Profit Margin | -211.24% | ↑ 115036.59% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 930.5K | ↓ 97.52% |
Net Income | -123.1M | ↑ 55.38% |
Net Profit Margin | -13.2K% | ↓ 13020.26% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 90.5M | ↑ 10366.54% |
Net Income | 76.0M | ↓ 166.45% |
Net Profit Margin | 84.0% | ↑ 13315.5% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 21.4M | ↓ 74.78% |
Net Income | -25.1M | ↓ 135.27% |
Net Profit Margin | -117.45% | ↓ 201.45% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 31.2M | ↑ 41.45% |
Net Income | -31.5M | ↑ 21.81% |
Net Profit Margin | -101.15% | ↑ 16.3% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.6M | ↑ 23.97% |
Net Income | -10.4M | - |
Net Profit Margin | -138.0% | - |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.5M | ↑ 51.96% |
Net Income | -20.9M | ↑ 100.0% |
Net Profit Margin | -181.62% | ↓ 43.62% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.0M | ↓ 75.46% |
Net Income | -4.3M | ↓ 80.72% |
Net Profit Margin | -142.65% | ↑ 38.97% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 17.1M | ↑ 19.75% |
Net Income | -8.0M | - |
Net Profit Margin | -47.06% | - |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 261.0M | ↓ 21.73% |
Total Liabilities | 237.2M | ↑ 10.36% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 344.3M | ↑ 35.03% |
Total Liabilities | 250.9M | ↑ 8.27% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 241.6M | ↓ 35.9% |
Total Liabilities | 261.2M | ↓ 4.88% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 318.5M | ↑ 41.84% |
Total Liabilities | 183.8M | ↓ 24.28% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 228.1M | ↓ 23.49% |
Total Liabilities | 128.1M | ↓ 25.59% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 173.3M | ↓ 19.58% |
Total Liabilities | 105.9M | ↓ 12.47% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 228.1M | - |
Total Liabilities | 128.1M | - |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 207.5M | ↓ 10.04% |
Total Liabilities | 127.8M | ↓ 1.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 210.3M | ↑ 0.0% |
Total Liabilities | 129.5M | ↑ 0.0% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 173.9M | ↓ 10.33% |
Total Liabilities | 105.9M | ↓ 11.28% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 189.7M | ↑ 0.0% |
Total Liabilities | 115.5M | ↑ 0.0% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 173.3M | ↓ 0.3% |
Total Liabilities | 105.9M | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -63.8M | ↑ 12.49% |
Investing Cash Flow | -4.5M | ↑ 35.21% |
Financing Cash Flow | -7.4M | ↓ 103.74% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -53.0M | ↓ 14.98% |
Investing Cash Flow | 363.4K | ↓ 108.2% |
Financing Cash Flow | 129.9M | ↓ 1893.98% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -117.2M | ↑ 102.12% |
Investing Cash Flow | -1.2M | ↓ 395.41% |
Financing Cash Flow | -10.0M | ↓ 107.06% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 112.9M | ↓ 203.68% |
Investing Cash Flow | -3.8M | ↑ 249.59% |
Financing Cash Flow | -10.1M | ↑ 7.99% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -12.6M | ↓ 74.1% |
Investing Cash Flow | 1.3M | ↓ 1447.74% |
Financing Cash Flow | -921.5K | ↑ 2.05% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -12.5M | ↓ 0.26% |
Investing Cash Flow | 1.3M | ↑ 0.0% |
Financing Cash Flow | -882.0K | ↓ 4.29% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -12.5M | ↑ 0.0% |
Investing Cash Flow | 1.3M | ↑ 0.0% |
Financing Cash Flow | -882.0K | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -25.8M | ↑ 106.13% |
Investing Cash Flow | 1.3M | ↑ 0.0% |
Financing Cash Flow | -995.0K | ↑ 12.81% |
Sell
Neutral
Buy
Genfit Sa is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Genfit Sa | 2.22% | 16.41% | 7.79% | 1.22% | -75.72% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Genfit Sa | NA | NA | NA | 0.0 | -0.36 | -0.1 | NA | 1.37 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Genfit Sa | Buy | $211.0M | -75.72% | NA | -83.79% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Genfit Sa
Revenue is up for the last 3 quarters, 2.81M → 17.08M (in $), with an average increase of 48.4% per quarter
Netprofit is down for the last 2 quarters, -4.01M → -8.03M (in $), with an average decrease of 100.0% per quarter
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 29.3%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 68.0%
Morgan Stanley - Brokerage Accounts
genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as nash - nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). genfit is committed to contribute to bringing new medicines to market for patients who lack suitable solutions, and strives to implement mutually beneficial approaches that combine novel drugs and biomarkers. its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including genfit’s lead proprietary compound, gft505, that is completing a phase 2b study in nash.
Organization | Genfit Sa |
Employees | 159 |
CEO | Mr. Jean-Francois Mouney |
Industry | Biotechnology |
A Spac I Acquisition Corp
$4.15
-0.95%
Keyarch Acquisition Corp
$4.15
-0.95%
Connexa Sports Technologies Inc
$4.15
-0.95%
Us Value Etf
$4.15
-0.95%
First Wave Biopharma Inc
$4.15
-0.95%
Global X Msci Next Emerging
$4.15
-0.95%
Fat Projects Acquisition Corp
$4.15
-0.95%
Capital Link Global Fintech
$4.15
-0.95%
Applied Uv Inc
$4.15
-0.95%